Literature DB >> 11889242

Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI.

J Suhy1, R G Miller, R Rule, N Schuff, J Licht, V Dronsky, D Gelinas, A A Maudsley, M W Weiner.   

Abstract

OBJECTIVE: To determine 1) the reproducibility of metabolite measurements by (1)H MRS in the motor cortex; 2) the extent to which (1)H MRS imaging (MRSI) detects abnormal concentrations of N-acetylaspartate (NAA)-, choline (Cho)-, and creatine (Cre)-containing compounds in early stages of ALS; and 3) the metabolite changes over time in ALS.
METHODS: Sixteen patients with definite or probable ALS, 12 with possible or suspected ALS, and 12 healthy controls underwent structural MRI and multislice (1)H MRSI. (1)H MRSI data were coregistered with tissue-segmented MRI data to obtain concentrations of NAA, Cre, and Cho in the left and right motor cortex and in gray matter and white matter of nonmotor regions in the brain.
RESULTS: The interclass correlation coefficient of NAA was 0.53 in the motor cortex tissue and 0.83 in nonmotor cortex tissue. When cross-sectional data for patients were compared with those for controls, the NAA/(Cre + Cho) ratio in the motor cortex region was significantly reduced, primarily due to increases in Cre and Cho and a decrease in NAA concentrations. A similar, although not significant, trend of increased Cho and Cre and reduced NAA levels was also observed for patients with possible or suspected ALS. Furthermore, in longitudinal studies, decreases in NAA, Cre, and Cho concentrations were detected in motor cortex but not in nonmotor regions in ALS.
CONCLUSION: Metabolite changes measured by (1)H MRSI may provide a surrogate marker of ALS that can aid detection of early disease and monitor progression and treatment response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889242      PMCID: PMC2733360          DOI: 10.1212/wnl.58.5.773

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging.

Authors:  B J Soher; K Young; V Govindaraju; A A Maudsley
Journal:  Magn Reson Med       Date:  1998-12       Impact factor: 4.668

2.  1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis.

Authors:  W G Bradley; B C Bowen; P M Pattany; F Rotta
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

3.  MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis.

Authors:  B C Bowen; P M Pattany; W G Bradley; J B Murdoch; F Rotta; A A Younis; R C Duncan; R M Quencer
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

4.  1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla.

Authors:  E P Pioro; A W Majors; H Mitsumoto; D R Nelson; T C Ng
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

5.  Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain.

Authors:  S Chan; D C Shungu; A Douglas-Akinwande; D J Lange; L P Rowland
Journal:  Radiology       Date:  1999-09       Impact factor: 11.105

6.  Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo.

Authors:  E P Pioro; J P Antel; N R Cashman; D L Arnold
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

7.  A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings.

Authors:  C M Ellis; A Simmons; C Andrews; J M Dawson; S C Williams; P N Leigh
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

8.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types.

Authors:  J Urenjak; S R Williams; D G Gadian; M Noble
Journal:  J Neurosci       Date:  1993-03       Impact factor: 6.167

9.  Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements.

Authors:  W Block; J Karitzky; F Träber; C Pohl; E Keller; R R Mundegar; R Lamerichs; H Rink; F Ries; H H Schild; F Jerusalem
Journal:  Arch Neurol       Date:  1998-07

10.  Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.

Authors:  S Kalra; N R Cashman; A Genge; D L Arnold
Journal:  Neuroreport       Date:  1998-06-01       Impact factor: 1.837

View more
  33 in total

1.  Advances in the application of MRI to amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michel Modo
Journal:  Expert Opin Med Diagn       Date:  2010-11

Review 2.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

3.  GAVA: spectral simulation for in vivo MRS applications.

Authors:  Brian J Soher; Karl Young; Aaron Bernstein; Zakaria Aygula; Andrew A Maudsley
Journal:  J Magn Reson       Date:  2007-01-12       Impact factor: 2.229

4.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

Review 5.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

6.  Magnetic resonance spectroscopic imaging detects abnormalities in normal-appearing frontal lobe of patients with Sturge-Weber syndrome.

Authors:  Carlos E A Batista; Harry T Chugani; Jiani Hu; E Mark Haacke; Michael E Behen; Emily J Helder; Csaba Juhász
Journal:  J Neuroimaging       Date:  2008-07       Impact factor: 2.486

7.  Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS.

Authors:  J D Carew; G Nair; P M Andersen; J Wuu; S Gronka; X Hu; M Benatar
Journal:  Neurology       Date:  2011-09-21       Impact factor: 9.910

Review 8.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Reproducibility of serial whole-brain MR spectroscopic imaging.

Authors:  A A Maudsley; C Domenig; S Sheriff
Journal:  NMR Biomed       Date:  2010-04       Impact factor: 4.044

10.  Numerical simulations of localized high field 1H MR spectroscopy.

Authors:  Lana G Kaiser; Karl Young; Gerald B Matson
Journal:  J Magn Reson       Date:  2008-08-28       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.